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ABSTRACT
Objectives: The aim of the study was to assess the role of HE4 and CA125 in differentiation between malignant and 
non-malignant endometrial pathologies. 
Material and methods: A retrospective study of 87 patients with endometrial pathologies was conducted. Tumor markers 
were assessed two weeks before surgical intervention in each subject. The final diagnosis was established on the basis of 
the histopathological examination of the endometrium. 
Results: Serum HE4 levels were significantly higher in patients with endometrial cancer (EC) as compared to non-malignant 
endometrial pathologies (p < 0.001), patients with stage I EC as compared to non-malignant endometrial pathologies 
(p < 0.001), and patients with stage Ia EC as compared to non-malignant endometrial pathologies (p = 0.003). Serum 
CA125 levels were not significantly different as far as these groups of patients were concerned. Both tumor markers were 
significantly higher in patients with stage II-III as compared to stage I EC and non-malignant endometrial pathologies 
(p < 0.001 for both markers). Sensitivity and specificity of HE4 at the cut-off level of 70 pmol/L for detecting endometrial 
malignancies were 73.08% and 85.71%, respectively. Sensitivity and specificity of CA125 at the cut-off level of 35 U/mL were 
29.41% and 94.29%, respectively. The area under the curve (AUC) for HE4 was 0.875, suggesting that this marker reliably 
differentiates malignant from non-malignant endometrial pathologies (p < 0.001). AUC for CA125 was 0.552, suggesting 
that this marker does not reliably differentiate between malignant and non-malignant endometrial pathologies (p = 0.414). 
Conclusion: HE4, in contrast to CA125, might be a useful tool for detecting malignant endometrial pathologies.
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INTRODUCTION
Endometrial cancer (EC) is the sixth most common ma-
lignancy among women worldwide and the fourteenth 
most common cancer overall. Poland has the 16th high-
est rate of EC globally, with an age-standardized rate of 
16.9 per 100 000 women. In 2012, a total of 320 000 new 
cases were diagnosed in the world [1]. The incidence rate 
is higher in the developed countries [1, 2]. The majority 
of EC cases are diagnosed in the early stages due to early 
symptommaticity. As a result, the 5-year survival rate for 
all EC stages has been estimated at 80% [3]. Endometrial 
hyperplasia is characterized by non-invasive proliferation 
of the endometrial epithelium and can be further classified 
as simple or complex, with or without atypia, depending on 
architecture complexity and nuclear cytology. The existence 
of endometrial hyperplasia is associated with the develop-
ment of EC [4]. An endometrial polyp is a localized hyper-
plastic growth of the endometrial stroma and glands [5]. 
The etiology of all these histological changes is related to 
an excess of estrogen exposure, together with insufficient 
progesterone levels [5,6]. Cancer antigen 125 (CA125) was 
described for the first time by Bast et al. [7], and has been 
widely used in ovarian cancer (OC) ever since. However, 
its levels can be elevated in healthy individuals, as well 
as in many malignant and non-malignant gynecological 
and non-gynecological diseases [8]. Human epididymis 
protein 4 (HE4) is the product of the HE4 gene, located 
on chromosome 20q 12-13.1 [8]. The initial evidence that 
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HE4 can act as an oncogenic or tumor-promoting agent 
was shown in an experimental study of Li et al. [9]. HE4 and 
CA125 have been widely used in routine management of 
OC [10]. Recent studies have considered the role of HE4 in 
the diagnosis, staging and prognosis of EC [11–13]. In this 
study, we present our experience in the assessment of the 
role of HE4 and CA125 in differentiating between malignant 
and non-malignant endometrial pathologies. 
The aim of the study was to assess the diagnostic per-
formance of tumor markers HE4 and CA125 in differentiat-
ing between malignant and non-malignant endometrial 
pathologies and to search for statistically significant differ-
ences between serum HE4 and CA125 levels in patients with 
malignant and non-malignant endometrial pathologies. 
MATERIAL AND METHODS
A retrospective study of 87 patients admitted to our 
clinic between October 2012 and June 2015 was conducted. 
All patients with endometrial pathologies were reviewed 
and their eligibility for the study was verified. The inclusion 
criteria were as follows: age > 18 years and serum levels 
of HE4 and CA125 within two weeks before the surgical 
intervention, in which histological material was obtained 
and analyzed later on by a pathologist. Only tumor marker 
measurements from the proliferative phase of a regular 
menstrual cycle taken into consideration. The reason for 
surgical operation in case of non-malignant endometrial 
pathologies was abnormal uterine bleeding. The exclusion 
criteria were as follows: hepatic and renal diseases, simulta-
neous adnexal disease, uterine fibroids > 5 cm, secondary 
malignancy, and history of chemotherapy or radiotherapy. 
EC staging was performed according to the International 
Federation of Gynecology and Obstetrics (FIGO) criteria. 
The final histological diagnosis was made according to the 
1994 World Health Organization (WHO) classification [6]. 
Both, HE4 and CA125 were measured simultaneously with 
kits (Fujirebio Diagnostics, Inc.), in the same apparatus Cobas 
8000 e602, using Electro-chemiluminescence immunoassay 
(ECLIA). 
The Shapiro-Wilk (S-W) test was used to check variable 
distribution of the tumor markers. Sensitivity, specificity, 
positive predictive value, negative predictive value, and 
accuracy of the tumor markers were calculated. Then, the 
diagnostic performance of HE4 and CA125 for detecting 
malignancy was analyzed using the chi-squared test. The 
p-value of < 0.05 was considered as statistically significant. 
Statistical Package for the Social Sciences (SPSS) Software 
was used for statistical analysis. 
RESULTS
A total of 87 patients (aged 27–86 years) were included 
in the study. Mean age was 61.8 years (standard devia-
tion (SD) = 13.2 years, median: 64 years). The majority of 
the patients (64, 73.56%) were post-menopausal and only 
23 (26.44%) were pre-menopausal. There were 52 (59.77%) 
patients with EC. A total of 46 (88.46%) subjects were diag-
nosed with endometrioid EC, while 4 (7.69%) and 2 (3.85%) 
women were diagnosed with serous and clear cell car-
cinoma subtypes, respectively. The number of patients 
with histological grading G1, G2, and G3 was 34 (73.9%), 
9 (19.5%), and 3 (6.5%), respectively. Serum HE4 levels in 
these groups of patients were 91.70 ,120, and 213 pmol/L, 
respectively, while CA125 levels were 16.11, 22.3. and 
96.3 U/mL, respectively. 
The number of patients with stage I, II and III was 
37 (71.15%), 3 (5.77%), and 12 (23.08%), respectively. Within 
stage I, 19 (51.35%) and 18 (48.65%) women were diag-
nosed with stage Ia and Ib disease, respectively. A total of 
35 (40.23%) subjects were diagnosed with pathologies of 
the endometrium other than malignancy. Only 2 (5.71%) 
patients were diagnosed with hyperplasia with atypia. 
A total of 33 (94.29%) patients were diagnosed with other 
pathologies, including 17 (48.57%) women with endome-
trial polyps, 2 (5.71%) with hyperplasia without atypia, and 
14 (40.00%) with both, endometrial polyp and hyperplasia 
without atypia. The statistical significance of the S-W test 
was < 0.001 for both tumor markers. The distribution of the 
variables was not normal. Therefore, non-parametric tests 
(Mann-Whitney U test and Kruskal-Wallis test) were used 
to assess whether serum HE4 and/or CA125 levels were 
significantly different between certain groups of patients 
with endometrial pathologies. The results of these statistical 
analyses are shown in Table 1.
Serum HE4 levels were significantly higher in patients 
with EC as compared to non-malignant endometrial pathol-
ogies (p < 0.001), with stage I EC as compared to non-ma-
lignant endometrial pathologies (p < 0.001), and with stage 
Ia EC as compared to non-malignant endometrial patholo-
gies (p = 0.003). Serum CA125 levels were not significantly 
different among these groups of patients. Both, HE4 and 
CA125 were significantly higher in patients with stage II–III 
as compared to stage I EC and non-malignant endometrial 
pathologies (p < 0.001 for both markers). Neither HE4 nor 
CA125 were significantly higher in patients with endometrial 
hyperplasia with atypia as compared to other non-malignant 
endometrial pathologies. The diagnostic performance of the 
tumor markers in differentiating between malignant and 
non-malignant endometrial pathologies at certain cut-off 
levels is shown in Table 2. The results of the chi-squared test 
with p-values are presented in Table 3. 
A receiver operating characteristic (ROC) curve was con-
structed to compare both tumor markers (HE4 and CA125) as 
far as differentiation between malignant and non-malignant 
endometrial pathologies was concerned. The area under 
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Table 1. Comparison of different groups of patients with regard to HE4 and CA125
Compared groups Group
Number of patients 
(out of the total of the 
compared groups)
HE4 CA125
Median level 
[pmol/L] p-value
Median level 
[U/mL] p-value
EC vs. non-malignant 
endometrial pathologies
EC 52 (59.8%) 97.25
 < 0.001
18.56
0.414Non-malignant 
endometrial pathologies 35 (40.2%) 41.80 17.99
Stage Ia EC vs. non- 
-malignant endometrial 
pathologies
Stage Ia EC 19 (35.2%) 73.20
0.003
12.82
0.065Non-malignant 
endometrial pathologies 35 (64.8%) 41.80 17.99
Stage I EC vs. non- 
-malignant endometrial 
pathologies
Stage I EC 37 (51.4%) 89.20
 < 0.001
15.72
0.398Non-malignant 
endometrial pathologies 35 (48.6%) 41.80 17.99
Stage II–III EC vs. non- 
-malignant endometrial 
pathologies
Stage II–III EC 15 (30%) 176.60
 < 0.001
66.03
 < 0.001Non-malignant 
endometrial pathologies 35 (70%) 41.80 17.99
Stage II–III EC vs. non- 
-malignant endometrial 
pathologies and stage I EC
Stage II–III EC 15 (17.2%) 176.60
 < 0.001
66.03
 < 0.001Non-malignant 
endometrial pathologies 
and stage I EC
72 (82.8%) 57.45 16.17
Hyperplasia with atypia 
vs. other non-malignant 
endometrial pathologies
Hyperplasia with atypia 2 (5.71%) 41.10
0.659
12.89
0.484Other non-malignant 
endometrial pathologies 33 (94.3%) 41.80 20.26
Table 2. The diagnostic performance of HE4 and CA125 for detecting EC 
The diagnostic test  
with the cut-off level
Sensitivity  
(95% CI)
Specificity  
(95% CI)
Positive 
predictive value
(95% CI)
Negative 
predictive value
(95% CI)
Accuracy  
(95% CI)
CA125
Cut-off level 35 U/mL
29.41% 
(17–42)
94.29% 
(87–100)
88.24% 
(73–100)
47.83% 
(36–60)
55.81% 
(45–66)
HE4
Cut-off level 70 pmol/L
73.08% 
(61–85)
85.71% 
(74–97)
88.37% 
(79–98)
68.18% 
(54–82)
78.16% 
(69–87)
HE4 
Cut-off level 150 pmol/L
28.85% 
(17–41)
100.00% 
(100–100)
100.00% 
(100–100)
48.61% 
(37–60)
57.47% 
(47–68)
HE4
Cut-off level 70 for pre- and 150 pmol/L 
for post-menopausal patients
28.85% 
(17–41)
97.14% 
(92–100)
93.75% 
(82–100)
47.89% 
(36–60)
56.32% 
(46–67)
the curve (AUC) is shown in Figure 1. AUC for both tumor 
markers with statistical significance is shown in Table 4.
ROC-AUC for HE4 was 0.875, suggesting that HE4 reliably 
differentiates between malignant and non-malignant endo-
metrial pathologies (p < 0.001), whereas AUC for CA125 was 
0.552, suggesting that CA125 does not reliably differentiate 
between malignant and non-malignant endometrial patholo-
gies (p = 0.414). The Hanley and McNeil method was used 
to compare the AUC of tumor markers, and revealed that 
HE4 was significantly more important than CA125 as far as reli-
able differentiation between malignant and non-malignant 
endometrial pathologies was concerned (Z = 4.42; p < 0.001).
DISCUSSION
At present, there is no single tumor marker that can be 
used for the diagnosis, monitoring and follow-up of EC. In 
1991 Kirchhoff et al., described for the first time HE4 in the 
distal part of the epididymis [14]. HE4, along with CA125 and 
the menopausal status, is used to determine the risk of 
malignancy through an algorithm in patients with adnexal 
tumors [15]. Recent studies have shown that HE4 levels are 
elevated in patients with EC [11, 16, 17]. The role of tumor 
markers in detecting early stages of EC may be limited since 
postmenopausal bleeding is an early symptom of the dis-
ease [18]. However, elevated levels of HE4 may be of great 
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importance for patients at high risk of EC, such as patients 
with hereditary non-polyposis colorectal cancer (HNPCC) 
syndrome [19]. One of the most important issues is the diag-
nosis of EC in young women, for whom a fertility-preserving 
treatment is the preferable choice [12].
In this study, we used the WHO classification which 
adopted four categories of hyperplasia (simple or complex 
hyperplasia, with or without atypia). This classification was 
modified in 2014 into two categories: hyperplasia without 
atypia and atypical hyperplasia/endometrioid intraepithe-
lial neoplasia. The new classification is simpler to imple-
ment in clinical practice, particularly regarding the choice 
of treatment. We considered atypical hyperplasia as one 
group since it is associated with a high relative risk of pro-
gression into invasive carcinoma [6]. Tumor markers were 
measured in the proliferative phase of the menstrual cycle. 
In the study of Anastasi et al. significant fluctuation of the 
HE4 level was observed in different phases of the menstrual 
cycle. The peak level of HE4 was observed during the ovula-
tory phase. The HE4 level was significantly higher during 
the ovulatory phase as compared to the follicular phase in 
women < 35 years. This statistically significant difference 
was not observed in patients > 35 years. Serum CA125 level 
was not significantly different considering different phases 
of the menstrual cycle in both age groups [20]. 
To the best of our knowledge, there has been no consen-
sus about the optimal HE4 level to diagnose EC [11, 17]. In 
our study, the cut-off level for HE4 was set at different levels, 
taking into account the menopausal status of the patients. In 
the study of Escudero et al. their results showed higher 
HE4 serum concentrations in postmenopausal as compared 
to premenopausal patients [8]. We believe that including 
the menopausal status into the cut-off level of HE4 in our 
study reflects greater accuracy of the results, since we expect 
fewer false positive results among postmenopausal patients. 
Table 3. Results of the chi-squared test and p-values for CA125 and HE4 in differentiating between malignant and non-malignant endometrial 
pathologies 
The diagnostic test  
with the cut-off level
Type of endometrial 
pathology according 
to the diagnostic test
Final histological diagnosis
Result of chi2 
test and  
p-value
Non-malignant endometrial 
pathologies
Malignant endometrial 
pathologies
Number of 
patients
Percent of 
the total
Number of 
the patients
Percent of 
the total
CA125
Cut-off level 35 U/mL
Non-malignant 33 94.29 36 70.59 chi2(1) = 7.35
 p = 0.007,Malignant 2 5.71 15 29.41
HE4
Cut-off level 70 pmol/L
Non-malignant 30 85.71 14 26.92 chi2(1) = 28.93
p < 0.001 Malignant 5 14.29 38 73.08
HE4 
Cut-off level 150 pmol/L
Non-malignant 35 100.00 37 71.15 chi2(1) = 12.00 
p < 0.001Malignant 0 0 15 28.85
HE4
Cut-off level 70 for premenopausal 
patients and 150 pmol/L for 
postmenopausal patients 
Non-malignant 34 97.14 37 71.15
chi2(1) = 9.41 
p = 0.002
Malignant 1 2.86 15 28.85
Table 4. ROC-AUC for HE4 [pmol/L] and CA125 [U/mL] in diagnosing malignant endometrial pathologies in 87 patients included in the study 
Tumor marker AUC 95% CI p-value
HE4 0.875 0.802–0.948  < 0.001
CA125 0.552 0.430–0.674 0.414
Figure 1. ROC-AUC for HE4 and CA125 in differentiating between 
malignant and non-malignant endometrial pathologies
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Patients with renal disease were excluded from the study 
in order to reduce the false positive rate of HE4 among pa-
tients with renal disease. In a study of Lv et al. a higher level 
of HE4 was observed in patients with chronic renal disease 
as compared to OC and EC, although the difference was not 
statistically significant. In their study, no statistically signifi-
cant differences in CA125 serum levels between patients 
with chronic renal disease and controls were observed [21].
Although the role of CA125 in the diagnosis, staging and 
prognosis of EC has been widely investigated, at present 
CA125 is not routinely used in the clinical practice [8, 22, 23]. 
In modern practice, the role of the novel marker HE4 is still 
under investigation, although the recent reports on HE4 in 
the literature are promising. 
In the study of Li et al. immunohistochemistry was used 
to detect HE4 expression in 102 cases of EC, 30 cases of 
endometrial hyperplasia, and 20 cases of normal endome-
trium. The expression of HE4 in the tissues was confirmed in 
84.62%, 66.67% and 15% cases of EC, atypical hyperplasia, 
and normal endometrium, respectively. HE4 expression was 
significantly higher in EC as compared to atypical hyper-
plasia and normal endometrium. Moreover, a significantly 
higher expression of HE4 was observed in poorly differen-
tiated malignancies as compared to highly differentiated 
malignancies [18]. Similar results were found in the study 
of Deng et al. In their study, HE4 expression in endometrial 
tissues was significantly higher in EC tissues as compared 
to the normal endometrium. HE4 was also significantly cor-
related with the degree of cancer differentiation [24]. 
In our study, significantly higher levels of HE4 were 
found in patients with malignant endometrial pathologies 
as compared to non-malignant endometrial pathologies. At 
the same time, there were no statistically significant differ-
ences in CA125 levels between these groups of patients. Our 
results are supported by the results of Antonsen et al., who 
reported a significantly higher level of HE4, in contrast to 
CA125, in patients with malignant endometrial pathologies 
as compared to atypical endometrial hyperplasia. The sensi-
tivity and specificity of HE4 at the cut-off level of 70 pmol/L 
in their study found that the ability to differentiate malig-
nancy from atypical endometrial hyperplasia was 43.9% 
and 76.5%, respectively, while the sensitivity and specificity 
of CA125 at the cut-off level of 35 U/mL were 19.7% and 
78.2%, respectively [25]. Our finding are also supported by 
results of Minar et al., in which a significant higher level of 
HE4 was found in patients with EC as compared to benign 
endometrial pathologies [26]
In the study of Chen et al. a significantly higher level of 
HE4 was found in patients with uterine cancer as compared 
to benign uterine disease, among all patients studied and 
among the premenopausal patients in particular. No such 
statistically significant difference was found among post-
menopausal patients. On the contrary, serum CA125 levels 
were not significantly different in the whole study popu-
lation, or either in premenopausal or postmenopausal 
group [27].
Gasiorowska et al. investigated for the first time the 
value of HE4 as a complementary diagnostic method in the 
management and diagnosis of EC in the Polish population. 
Their results revealed statistically significant differences 
of HE4 levels in differentiating between malignant and 
non-malignant endometrial pathologies . These authors 
demonstrated significant higher levels of HE4 in the ag-
gressive histological grades of EC. Patients who needed 
lymphadenectomy had significant higher levels of HE4, sug-
gesting that HE4 can be a useful preoperative counselling 
tool to identify those who may require pelvic and para-aortic 
lymphadenectomy [28].
Our study is not without certain limitations, chief among 
them lack of the control group. In the study of Presl et al. 
a significantly higher level of HE4 was found in patients 
with EC as compared to the control group. On the contrary, 
CA125 levels were not significantly different between the 
two groups [29]. However, the aim of our study was to as-
sess whether there existed a statistical difference of tumor 
marker levels between groups of patients with endometrial 
pathologies. The number of patients in our retrospective, 
single-center study was relatively small. Serum levels of both 
tumor markers did not differ significantly between patients 
with atypical hyperplasia and other endometrial patholo-
gies. These results should be considered with caution due 
to the low number of patients with atypical hyperplasia in 
our study. 
Serum HE4 levels were significantly elevated not only 
among patients with endometrial malignancies as com-
pared to non-malignant endometrial pathologies, but also 
among patients with stage Ia and stage I EC as compared 
to non-malignant endometrial pathologies. This may indi-
cate the usefulness of HE4 in detecting malignancy even 
in earlier stages of the disease. On the contrary, CA125 was 
not significantly different between groups of patients with 
EC, stage I and stage Ia, and with the group of patients 
with non-malignant endometrial pathologies. We believe 
that oncologists should consider our results with caution 
in daily clinical practice. 
Our findings concerning both tumor markers (HE4 and 
CA125) in the Polish population are in agreement with the 
results of the meta-analysis by Chen et al., assessing the role 
of these markers in the diagnosis of EC. A total of 1832 cases 
from 8 studies were enrolled in that meta-analysis. Control 
groups were represented by healthy subjects in 5 studies, 
benign endometrial cases in 2 studies, and a mixture of 
healthy and benign endometrial cases in 1 study. HE4 was 
superior to CA125 in diagnosing EC, with the area under 
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summary receiver operation characteristic curve for HE4 and 
CA125 being 0.77 and 0.37, respectively [30]. The useful-
ness of these tumor markers may provide an impetus to 
develop a model for predicting endometrial malignancy 
which uses tumor markers in combination with other clinical 
and radiological parameters for the purposes of risk stratifi-
cation. This algorithm can help in the early diagnosis of EC, 
precise pre-surgical staging of the disease, eliminating the 
necessity for lymphadenectomy, and appropriate methods 
for follow-up to detect recurrence as early as possible [28].
CONCLUSIONS
In patients with endometrial pathologies, serum HE4 lev-
el may be a useful marker for detecting endometrial malig-
nancies, even during the early stages of disease. 
Serum CA125 level is not useful in differentiating be-
tween malignant and non-malignant endometrial patholo-
gies.
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